BR112014002546A2 - "colágeno 7, ou seu fragmento funcional, seus métodos de produção e de purificação, sua preparação purificada ou isolada, vetor, coleção de vetores, preparação isolada de células, cultura celular, e método para produção de uma célula adequada à expressão de colágeno 7" - Google Patents

"colágeno 7, ou seu fragmento funcional, seus métodos de produção e de purificação, sua preparação purificada ou isolada, vetor, coleção de vetores, preparação isolada de células, cultura celular, e método para produção de uma célula adequada à expressão de colágeno 7"

Info

Publication number
BR112014002546A2
BR112014002546A2 BR112014002546A BR112014002546A BR112014002546A2 BR 112014002546 A2 BR112014002546 A2 BR 112014002546A2 BR 112014002546 A BR112014002546 A BR 112014002546A BR 112014002546 A BR112014002546 A BR 112014002546A BR 112014002546 A2 BR112014002546 A2 BR 112014002546A2
Authority
BR
Brazil
Prior art keywords
collagen
cell
preparation
isolated
functional fragments
Prior art date
Application number
BR112014002546A
Other languages
English (en)
Portuguese (pt)
Inventor
Viswanathan Malini
De Souza Mark
Original Assignee
Lotus Tissue Repair Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lotus Tissue Repair Inc filed Critical Lotus Tissue Repair Inc
Publication of BR112014002546A2 publication Critical patent/BR112014002546A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/13Dipeptidases (3.4.13)
    • C12Y304/13009Xaa-Pro dipeptidase (3.4.13.9) i.e. prolidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485Exopeptidases (3.4.11-3.4.19)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11002Procollagen-proline dioxygenase (1.14.11.2), i.e. proline-hydroxylase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
BR112014002546A 2011-08-03 2012-08-03 "colágeno 7, ou seu fragmento funcional, seus métodos de produção e de purificação, sua preparação purificada ou isolada, vetor, coleção de vetores, preparação isolada de células, cultura celular, e método para produção de uma célula adequada à expressão de colágeno 7" BR112014002546A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161514796P 2011-08-03 2011-08-03
PCT/US2012/049553 WO2013020064A1 (en) 2011-08-03 2012-08-03 Collagen 7 and related methods

Publications (1)

Publication Number Publication Date
BR112014002546A2 true BR112014002546A2 (pt) 2017-03-14

Family

ID=47629706

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002546A BR112014002546A2 (pt) 2011-08-03 2012-08-03 "colágeno 7, ou seu fragmento funcional, seus métodos de produção e de purificação, sua preparação purificada ou isolada, vetor, coleção de vetores, preparação isolada de células, cultura celular, e método para produção de uma célula adequada à expressão de colágeno 7"

Country Status (10)

Country Link
US (1) US9676837B2 (https=)
EP (1) EP2753704A4 (https=)
JP (2) JP2014524241A (https=)
KR (1) KR20140054160A (https=)
CN (2) CN103842517A (https=)
AU (2) AU2012289916B2 (https=)
BR (1) BR112014002546A2 (https=)
CA (1) CA2843896A1 (https=)
MX (1) MX351565B (https=)
WO (1) WO2013020064A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849257B2 (en) 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
FI3205351T3 (fi) 2010-04-23 2023-07-06 Alexion Pharma Inc Lysosomaalisen kertymätaudin entsyymi
KR20150038636A (ko) 2010-09-09 2015-04-08 시나게바 바이오파르마, 코포레이션 환자에서 리소좀 산 리파제 결핍증의 치료를 위한 리소좀 산 리파제의 용도
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
US9040484B2 (en) * 2011-04-26 2015-05-26 The Board Of Trustees Of The Leland Stanford Junior University Production and delivery of a stable collagen
EP3099801B1 (en) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
AU2015243535A1 (en) 2014-04-08 2016-11-03 University Of Southern California Polypeptide compositions with Type VII collagen fibronectin Type Ill- like repeats and treatment methods for wound closure and healing
KR102204367B1 (ko) * 2014-07-16 2021-01-19 주식회사 엘지생활건강 피부 주름 개선용 화장료 조성물
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
GB201601571D0 (en) * 2016-01-28 2016-03-16 Nordic Bioscience As Collagen type Vll alpha 1 assay
MX2018011162A (es) * 2016-03-16 2018-11-22 Phoenix Tissue Repair Inc Metodos de purificacion de colageno 7.
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
US11028146B2 (en) * 2017-09-22 2021-06-08 Modern Meadow, Inc. Recombinant yeast strains
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
CN109022464A (zh) * 2018-07-02 2018-12-18 西安巨子生物基因技术股份有限公司 重组人源型胶原蛋白的羟基化方法
CN114401769A (zh) * 2019-03-27 2022-04-26 菲尼克斯组织修复公司 生产胶原蛋白7组合物的系统和方法
EP3953380A4 (en) 2019-04-12 2023-01-25 Geltor, Inc. RECOMBINATION ELASTIN AND ASSOCIATED PRODUCTION
CA3145425A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
GB2610313B (en) 2020-01-24 2024-07-03 Geltor Inc Animal-free dietary collagen
KR20240004264A (ko) * 2021-03-04 2024-01-11 젤라텍, 인크. 배양된 동물 세포로부터의 콜라겐을 사용한 재료의 제조 방법
MX2024004434A (es) 2021-10-12 2024-07-09 Phoenix Tissue Repair Inc Terapia de reemplazo de proteínas con colágeno 7.
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法
CN116854807A (zh) * 2023-07-26 2023-10-10 浙江大学 一种重组人源ⅶ型胶原蛋白及其制备方法与应用
CN120137008B (zh) * 2025-03-18 2025-09-26 广东普言生物科技有限公司 一种重组Ⅶ型胶原蛋白Pro.C7及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142391A1 (en) * 1991-06-12 2002-10-03 Kivirikko Kari I. Synthesis of human procollagens and collagens in recombinant DNA systems
WO2001009318A1 (fr) * 1999-07-29 2001-02-08 Helix Research Institute Genes associes au cancer du foie
US7026463B2 (en) * 1999-08-13 2006-04-11 Matthew Glenn Polynucleotides and polypeptides, materials incorporating them and methods for using them
RU2002112751A (ru) 1999-11-12 2004-02-27 Файброджен, Инк. (Us) Рекомбинантные желатины
CN1552889A (zh) * 2003-12-18 2004-12-08 四川铭让生物科技有限公司 制备胶原蛋白和胶原多肽的方法及其用途
JP4490498B2 (ja) 2008-09-30 2010-06-23 新田ゼラチン株式会社 疾病抑制剤
US9040484B2 (en) 2011-04-26 2015-05-26 The Board Of Trustees Of The Leland Stanford Junior University Production and delivery of a stable collagen

Also Published As

Publication number Publication date
EP2753704A1 (en) 2014-07-16
AU2017254910A1 (en) 2017-11-23
JP2017209117A (ja) 2017-11-30
CA2843896A1 (en) 2013-02-07
US20150011733A1 (en) 2015-01-08
MX351565B (es) 2017-10-19
CN108165593A (zh) 2018-06-15
AU2012289916A1 (en) 2014-02-20
MX2014001383A (es) 2014-08-26
KR20140054160A (ko) 2014-05-08
EP2753704A4 (en) 2015-07-08
US9676837B2 (en) 2017-06-13
AU2012289916B2 (en) 2017-08-03
CN103842517A (zh) 2014-06-04
JP2014524241A (ja) 2014-09-22
WO2013020064A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
BR112014002546A2 (pt) "colágeno 7, ou seu fragmento funcional, seus métodos de produção e de purificação, sua preparação purificada ou isolada, vetor, coleção de vetores, preparação isolada de células, cultura celular, e método para produção de uma célula adequada à expressão de colágeno 7"
BR112012000942B8 (pt) processos para a produção de poliovírus, e para produzir uma vacina contra pólio
MX2009002388A (es) Uso de celulas humanas originarias de leucemia mieloide para la expresion de anticuerpos.
MY182355A (en) Hmo synthesis
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
BR112022003089A2 (pt) Métodos de produção de células progenitoras hemogênicas a partir de células-tronco pluripotentes
MX2010000393A (es) Metodo para el aislamiento y cultivo de celulas madre adultas derivadas del epitelio amniotico humano.
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
BR112012015596A2 (pt) "processo de produção de células aderentes e utilização das mesmas"
BR112017000690A2 (pt) geração de um banco de células mesênquimas do estroma a partir das células mononucleares reunidas de múltiplos doadores de medula óssea
BR112014018610A2 (pt) alfa-amilase
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
EA201000646A1 (ru) Способ получения биопрепарата (варианты)
PE20171131A1 (es) Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa)
EA201390215A1 (ru) Композиции и способы получения дендритных клеток
BR112014003841A2 (pt) estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
BRPI0721796A2 (pt) Ácido nucléico isolado, vetor de dna recombinante, célula hospedeira, método para aumentar a produção de 107891 ou de seus homólogos, microrganismo transformado, processo para produzir 107891, processo para produzir um precursor de 107891, método para produzir um lantibiótico diferente do 17891 e polipeptídeo isolado
BR112014012503A2 (pt) método para alta expressão de proteína recombinante de bactérias modificadas geneticamente e uso do mesmo
BR112012033396A2 (pt) Polipetídeo tendo atividade swollenin e seus usos.
MX2021012211A (es) Proceso de concentracion de litio y potasio a partir de arcillas provenientes de salares.
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
EA201000377A1 (ru) Способ получения фибробластоподобных клеток из пупочного канатика новорожденного
FI20115497A7 (fi) Menetelmä ja laitteisto hydroksikarboksyylihappotuotteen erottamiseksi
KR101733614B1 (ko) 젖산균 유래의 조효소액을 이용한 공액리놀레산의 제조방법

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2539 DE 03/09/2019 POR TER SIDO INDEVIDA.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]